Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma

被引:49
作者
Bonneau, Claire [1 ,6 ]
Rouzier, Roman [2 ]
Geyl, Caroline [3 ]
Cortez, Annie [4 ]
Castela, Mathieu [1 ]
Lis, Raphael [5 ]
Darai, Emile [1 ,6 ]
Touboul, Cyril [3 ,7 ]
机构
[1] Univ Paris 06, UMRS INSERM 938, F-75571 Paris 12, France
[2] Univ Versailles St Quentin En Yvelines, Inst Curie, Dept Surg, F-92210 St Cloud, France
[3] Hop Lariboisiere, UMR INSERM U965, F-75010 Paris, France
[4] Hop Tenon, Dept Pathol, F-75020 Paris, France
[5] Weill Cornell Med Coll, Dept Med Genet, Shahin Rafii Lab, Ansary Stem Cell Inst, New York, NY 10065 USA
[6] Univ Paris 06, Inst Univ Cancerol, Hop Univ Paris Est, Hop Tenon,AP HP,Dept Gynecol Obstet & Reprod Med, F-75020 Paris, France
[7] Univ Paris 12, Hop Intercommunal Creteil, Dept Obstet & Gynecol, F-94000 Creteil, France
关键词
Cancer associated stroma; Cancer stem cells; Chemoresistance; Cytokines; Ovarian carcinoma; CANCER STEM-CELLS; DRUG-RESISTANCE; CD44; EXPRESSION; TUMOR-CELLS; PACLITAXEL; INTERLEUKIN-8; CHEMOTHERAPY; GROWTH; ASSOCIATION; MANAGEMENT;
D O I
10.1016/j.ygyno.2014.10.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. DNA repair mechanisms, environment-mediated drug resistance and cancer initiating cells (CIC) are three major research concepts that can explain the chemoresistance of epithelial ovarian cancer (EOC). The objective was to test if changes in the expression of potential markers associated with drug resistance before and after chemotherapy would correlate with platinum resistance, defined as a recurrence within the first year after chemotherapy cessation, and with survival, in advanced EOC. Methods. We included 32 patients with stage IIIC-IV EOC who underwent laparoscopy to evaluate the extent of carcinomatosis, neoadjuvant chemotherapy (carboplatin/taxol) and interval surgery. Biopsies taken during the initial laparoscopies and interval surgeries were evaluated using immunohistochemisty for the expression of 7 proteins: CD117, CD44 and ALDH1 to evaluate CIC; IL-6, IL-8 and BMP2 to evaluate environmentmediated drug resistance; and ERCC1 to evaluate DNA repair. Expression measurements were correlated with platin resistance and survival. The markers' relevance was confirmed in vitro using chemoresistance tests and flow cytometric measurements of the proportion of CD44+ cells. Results. 17 patients were chemoresistant and 15 patients were chemosensitive. We observed increases in CD44, IL-6 and ERCC1 expression and stable ALDH1, CD117, IL-8, and BMP2 expression. Reduced expression of cancer initiating cell markers and increased expression of environment-mediated drug resistance markers were associated with poor prognosis. We also demonstrated that CD44+ cells had survival advantages in vitro. Conclusions. Changes in CD44 and IL-8 expression on tumor cells appeared to correlate with overall survival and should be further tested as predictors of chemoresistance using larger cohort. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 120
页数:9
相关论文
共 39 条
[1]   Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer [J].
Bapat, SA ;
Mali, AM ;
Koppikar, CB ;
Kurrey, NK .
CANCER RESEARCH, 2005, 65 (08) :3025-3029
[2]   Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells [J].
Bourguignon, Lilly Y. W. ;
Peyrollier, Karine ;
Xia, Weiliang ;
Gilad, Eli .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (25) :17635-17651
[3]   CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS [J].
CANNISTRA, SA ;
ABUJAWDEH, G ;
NILOFF, J ;
STROBEL, T ;
SWANSON, L ;
ANDERSEN, J ;
OTTENSMEIER, C .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1912-1921
[4]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[5]   Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts [J].
De Stefano, Ilaria ;
Battaglia, Alessandra ;
Zannoni, Gian Franco ;
Prisco, Maria Grazia ;
Fattorossi, Andrea ;
Travaglia, Daniele ;
Baroni, Silvia ;
Renier, Davide ;
Scambia, Giovanni ;
Ferlini, Cristiano ;
Gallo, Daniela .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) :107-116
[6]  
Garcia M., 2007, Global cancer facts and figures 2007
[7]   Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells [J].
Giridhar, Premkumar Vummidi ;
Funk, Holly M. ;
Gallo, Catherine A. ;
Porollo, Aleksey ;
Mercer, Carol A. ;
Plas, David R. ;
Drew, Angela F. .
CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (08) :887-897
[8]   A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study [J].
Gold, Michael A. ;
Brady, William E. ;
Lankes, Heather A. ;
Rose, Peter G. ;
Kelley, Joseph L. ;
De Geest, Koen ;
Crispens, Marta A. ;
Resnick, Kimberly E. ;
Howell, Stephen B. .
GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :635-639
[9]  
Haute Autorite de Sante Institut National du Cancer, 2010, GUID AFF LONG DUR CA
[10]  
Jacquet P, 1996, Cancer Treat Res, V82, P359